Publikationen PD Dr. Kern

  1. Kern U., Martin C., Scheicher S., Müller H. (2003)
    Treatment of phantom pain with botulinum-toxin A.
    A pilot study
    Schmerz 17, 117-124

  2. Kern U., Martin C., Scheicher S., Müller H. (2004)
    Long-term treatment of phantom- and stump pain with Botulinum toxin type A over 12 months.
    A first clinical observation
    Nervenarzt 75, 336-340

  3. Kern U., Martin C., Scheicher S., Müller H. (2006)
    Referred pain from amputation stump trigger points into the phantom limb.
    Schmerz 20, 300, 302-306

  4. Kern U., Busch V., Rockland M., Kohl M., Birklein F. (2009)
    Prevalence and risk factors of phantom limb pain and phantom limb sensations in Germany.
    A nationwide field survey
    Schmerz 23, 479-488

  5. Kern U., Kohl M., Kiefer R.-T. (2010)
    Lidocaine patch for therapy of neuropathic and non-neuropathic pain: A clinical case series of 87 patients.
    Nervenarzt 81, 1490-1497

  6. Kern U., Altkemper B., Kohl M. (2006)
    Management of phantom pain with a textile, electromagnetically-acting stump liner: a randomized, double-blind, crossover study
    J Pain Symptom Manage 32, 352-360

  7. Kern U., Kohl M., Seifert U., Schlereth T. (2011)
    Botulinum toxin type B in the treatment of residual limb hyperhidrosis for lower limb amputees: a pilot study.
    Am J Phys Med Rehabil 90, 321-329

  8. Kern U., Martin C., Scheicher S., Müller H. (2003)
    Botulinum toxin type A influences stump pain after limb amputations.
    J Pain Symptom Manage 26, 1069-1070

  9. Kern U., Martin C., Scheicher S., Müller H. (2004)
    Effects of botulinum toxin type B on stump pain and involuntary movements of the stump.
    Am J Phys Med Rehabil 83, 396-399

  10. Kern U. (2004)
    Influence of botulinum toxin on postamputation pain and phantom limbs.
    J Neurol Feb 251 Suppl 1, I/42

  11. Kern U., Martin C., Scheicher S., Müller H. (2004)
    Does botulinum toxin A make prosthesis use easier for amputees?
    J Rehabil Med 36, 238-239

  12. Koch H., Kern U., Busch V. (2009)
    Therapeutische Wirkung von Ausdauersport bei Migräne: Explorative Metaanalyse sportmedizinischer Studien.
    MMW-Forschritte der Medizin Originalien Nr.II, 59-62

  13. Reilich P., Fheodoroff K., Kern U., Mense S., Seddigh S., Wissel J., et al. (2004)
    Consensus statement: botulinum toxin in myofascial pain.
    J Neurol 251 Suppl 1, I36-38

  14. England J., Wagner T., Kern U., Roth-Daniek A., Sell A. (2011)
    The capsaicin 8% patch for peripheral neuropathic pain: practical guidance, hints and tips on the application process.
    Br J Nurs. 2011 Aug 11-Sep 8;20(15):926-31

  15. Kern U., Kohl M., Seifert U., Schlereth T. (2012)
    Botulinumtoxin Typ B lindert Stumpfschmerzen und Stumpfschwitzen - Chance zur indirekten Phantomschmerz-Reduktion durch bessere Prothesen-Nutzung?
    Schmerz. 2012 Apr;26(2):176-84

  16. Kern U., Busch V., Mueller R., Kohl M., Birklein F. (2012)
    Phantom limb pain in daily pratice - still a lot of work to do!
    Pain Med. 2012 Sep 26. doi:10.1111/j.1526-4637.2012.01494.x

  17. Mick G., Baron R., Kern U., Hans G., Finnerup N. B., Dworkin R. H. (2011)
    Localized neuropathic pain: clinical characteristics and a proposed definition.
    Pain Manage. (2012) 2(1), 71–77

  18. Wagner T., Roth-Daniek A., Sell A., England J., Kern U. (2012)
    The capsaicin 8% patch for peripheral neuropathic pain: Review of treatment best practice from 'real world' clinical experience.
    Pain Manage 2012;2: 239-250

  19. Kern U., Nolte T. (2008)
    25 years of progress in pain therapy: the rocky road to recognition.
    MMW Fortschr Med 150, 115-117

  20. Kiefer T.-R., Kern U., Bredanger S. (2008)
    Chronische Knieschmerzen: ein außergewöhnlicher Fall.
    Angewandte Schmerztherapie 2, 45-48

  21. Kern U. (2006)
    Botulinumtoxin beim myofaszialen Schmerzsyndrom.
    Schmerztherapie Nr.1 18-19

  22. Kern U., in Fayyaz A., Jost W.-H. (ed.) (2003)
    BTX - A in the treatment of Phantom Pain.
    Wissenschaftsverlag Wellingsbüttel Hamburg

  23. Kern U., in Junker U., Nolte T. (ed.) (2005)
    Grundlagen der speziellen Schmerztherapie.
    Verlag Medizin & Wissen, München

  24. Kern U., in Ningel R., Funke W. (ed.) (1995)
    Soziale Netzwerke in der Praxis.
    Verlag für angewandte Psychologie, Göttingen

  25. Busch V., Magerl W., Kern U., Haas J., Hajak G., Eichhammer P. (2012)
    The effect of deep and slow breathing on pain perception, autonomic activity and mood processing.
    An experimental study
    Pain Med. 2012 Feb;13(2):215-28

  26. Kern U., England J., Roth-Daniek A., Wagner T.
    Is physician supervision of the capsaicin 8% patch administration procedure really necessary?
    An opinion from health care professionals
    J Pain Res. 2013 Jul 19;6:571-5

  27. Kern U., Nalamachu S., Brasseur L., Zakrzewska J.-M.
    Can treatment success with 5% lidocaine medicated plaster be predicted in cancer pain with neuropathic components or trigeminal neuropathic pain?
    J Pain Res. 2013 Apr 5;6:261-80

  28. Kern U., Bialas P., Fangmann D.
    Prolonged-release tapentadol for phantom pain.
    A case series
    Schmerz. 2013 Apr 27;(2):174-81

  29. Treede R.-D., Wagner T., Kern U., Husstedt I.-W., Arendt G., Birklein F., Cegla T., Freynhagen R., Gockel H.-H., Heskamp M.-L., Jager H., Joppich R., Maier C., Leffler A., Nagelein H.-H., Rolke R., Seddigh S., Sommer C., Stander S., Wasner G., Baron R.
    Mechanism- and experience-based strategies to optimize treatment response to the capsaicin 8% cutaneous patch in patients with localized neuropathic pain.
    Curr Med Res Opin. 2013 May 29&;(5):527-38

  30. Baron R., Kern U., Müller M., Dubois C., Falke D., Steigerwald I.
    Effectiveness and olerability of a Moderate Dose of Tapentadol Prolonged Release for Managing Severe, Chronic Low Back Pain with a Neuropathic Component: An Open-label Continuation Arm of a Randomized Phase 3b Study.
    Pain Pract. 2014 Apr 18

  31. Kern U., Nowack W., Poole C.
    Treatment of neuropathic pain with the capsaicin 8% patch: is pretreatment with lidocaine necessary?
    Pain Pract. 2014 Feb 14;(2):E42-50

  32. Baron R, Kern U, Muller M et al. (2015)
    Effectiveness and Tolerability of a Moderate Dose of Tapentadol Prolonged Release for Managing Severe, Chronic Low Back Pain with a Neuropathic Component: An Open-label Continuation Arm of a Randomized Phase 3b Study.
    Pain practice : the official journal of World Institute of Pain 15:471-486

  33. Kern KU, Baust H, Hofmann W et al. (2014)
    Capsaicin 8 % cutaneous patches for phantom limb pain. Results from everyday practice (non-interventional study).
    Schmerz 28:374-383

  34. Kern KU, Bialas P, Fangmann D (2013)
    Prolonged-release tapentadol for phantom pain. A case series.
    Schmerz 27:174-181

  35. Kern KU, England J, Roth-Daniek A et al. (2013)
    Is physician supervision of the capsaicin 8% patch administration procedure really necessary? An opinion from health care professionals.
    Journal of pain research 6:571-575

  36. Kern KU, Krings D, Waldmann-Rex S (2014)
    Tapentadol prolonged release improves analgesia, functional impairment and quality of life in patients with chronic pain who have previously received oxycodone/naloxone.
    MMW Fortschritte der Medizin 156 Suppl 2:54-63

  37. Kern KU, Nalamachu S, Brasseur L et al. (2013)
    Can treatment success with 5% lidocaine medicated plaster be predicted in cancer pain with neuropathic components or trigeminal neuropathic pain?
    Journal of pain research 6:261-280

  38. Kern KU, Nowack W, Poole C (2014)
    Treatment of neuropathic pain with the capsaicin 8% patch: is pretreatment with lidocaine necessary?
    Pain practice : the official journal of World Institute of Pain 14:E42-50

  39. Sanchez Del Aguila MJ, Schenk M, Kern KU et al. (2015)
    Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain.
    Clinical therapeutics 37:94-113

  40. Schlereth T, Heiland A, Breimhorst M et al. (2015)
    Association between pain, central sensitization and anxiety in postherpetic neuralgia.
    European journal of pain 19:193-201

  41. Treede RD, Wagner T, Kern KU et al. (2013)
    Mechanism- and experience-based strategies to optimize treatment response to the capsaicin 8% cutaneous patch in patients with localized neuropathic pain.
    Current medical research and opinion 29:527-538

  42. Kern KU, Weiser T. (Dec. 2015)
    Topical ambroxol for the treatment of neuropathic pain : A first clinical observation.
    German version
    Schmerz, 29(6):632-40
    doi:10.1007/s00482-015-0065-6 (online verfügbar)

  43. Kern KU, Weiser T. (dec. 2015)
    Topical ambroxol for the treatment of neuropathic pain : An initial clinical observation.
    English version
    Schmerz, 29(Suppl 3):89-96
    (online verfügbar)
  44. Kern U (2013)
    Komponenten der Analgesie durch Akupunktur spezifiziert (Kommentar).
    JC Schmerzmed 2:213

  45. Kern U (2014)
    Die Faktoren für chronische Schmerzen nach Brustkrebs-OP (Kommentar).
    JC Schmerzmed 3:76-76

  46. Kern U (2015)
    Medikamentöse Kombinationstherapie bei Polyneuropathie (Kommentar).
    JC Schmerzmed 4:157-157

  47. Kern U (2015)
    Schmerzlinderung durch Berührung: Mechanismen genauer entschlüsselt (Kommentar).
    JC Schmerzmed 3:83

  48. Kern U (2016)
    Pharmakotherapie neuropathischer Schmerzen; Topische Therapien ergänzen bewährte systemische Konzepte.
    Deutsche Apothekerzeitung 156:46-52

  49. Kern U (2016)
    Neuraltherapeutische Injektionstechniken bei Rückenschmerz (Kommentar).
    JC Schmerzmed 5:129-129

  50. Baron R, Eberhart L, Kern KU et al. (2016)
    Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data.
    Pain practice : the official journal of World Institute of Pain

  51. Kern U (2016)
    Lokaltherapie mit Lidocain u. therapeutische Lokalanästhesie (Kap. 5); Lokaltherapie mit speziellen Substanzen (Kap. 7).
    In: Moderne Praxis der analgetischen Lokaltherapie, UNI-MED Science, 1. Aufl. (Editor C. Maihöfner)

  52. Lintzeris N, Bhaskar A, Kraus M et al. (2017)
    Consensus and controversies between pain and addiction experts on the prevention, diagnosis and management of opioid analgesic dependence.
    JAMA submitted

  53. Kern KU, Schwickert-Nieswandt M, Maihöfner C (2017)
    Topical ambroxol 20% for the treatment of classical trigeminal neuralgia and trigeminal neuropathy: first clinical reports.
    Headache submitted

  54. Maihöfner C, Schneider S, Bialas P, Gockel H, Beer K-G, Bartels M, Kern KU (2017)
    Successful treatment of complex regional pain syndrome with topical ambroxol: a case series.
    Pain management, accepted

  55. Poehlke T, Gralow I, Kern U et al. (2017)
    Empfehlungen zur Substitutionstherapie mit Buprenorphin/Naloxon bei behandlungsbedürftiger Medikamentenabhängigkeit von Opioiden.
    Sonderveröffentlichung

  56. Baron R, Treede RD, Birklein F et al. (2017)
    Treatment of painful radiculopathies with capsaicin 8% cutaneous patch.
    Current medical research and opinion:1-25

  57. Kern U, Krings D, Waldmann-Rex S (2017)
    Tapentadol Prolonged Release Improves Analgesia, Functional Impairment and Quality of Life in Patients with Chronic Pain who have Previously Received Oxycodone/Naloxone.
    J Pain Relief 6:281.
    doi 10.4172/2167-0846.1000281

  58. Kern KU, Schwickert M (2017)
    Ambroxol for the treatment of fibromyalgia: science or fiction?
    Journal of pain research 10:1905-1929

  59. Kern KU, Schwickert-Nieswandt M (2018)
    Erfolgreiche Therapie einer Post-Zoster-Neuralgie des linken Trigeminusastes V1 mit Capsaicin 8%-Pflaster
    Der Schmerz submitted

 
Zum Seitenanfang